Invading one step at a time: The role of invadopodia in tumor metastasis

Oncogene

Volumn 33, Issue 33, 2014, Pages 4193-4202

  Paz, H ^a   Pathak, N ^a,b   Yang, J ^a,b,c  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

invadopodia; metastasis; tumor invasion

Indexed keywords

ADAPTOR PROTEIN; CORTACTIN; INTEGRIN; MENA PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

CANCER THERAPY; CELL MEMBRANE; EXTRACELLULAR MATRIX; HUMAN; INTRACELLULAR SIGNALING; INVADOPODIA; MEMBRANE STRUCTURE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TUMOR CELL; TUMOR INVASION;

ADAM PROTEINS; ANIMALS; CELL SURFACE EXTENSIONS; CYTOSKELETON; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASE 14; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84906217473     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.393     Document Type: Review

References (127)

1. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
2. Linder S. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol 2007; 17: 107-117. (Pubitemid 46341826)
3. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 2011; 12: 413-426.
4. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001; 20: 6418-6434. (Pubitemid 32977848)
5. Okamura H, Resh MD. p80/85 cortactin associates with the Src SH2 domain and colocalizes with v-Src in transformed cells. J Biol Chem 1995; 270: 26613-26618. (Pubitemid 3006243)
6. Huang C, Liu J, Haudenschild CC, Zhan X. The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 1998; 273: 25770-25776. (Pubitemid 28475803)
7. Bowden ET, Barth M, Thomas D, Glazer RI, Mueller SC. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene 1999; 18: 4440-4449. (Pubitemid 29396652)
8. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006; 66: 3034-3043.
9. Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM et al. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res 2006; 312: 1240-1253.
10. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M et al. Molecular Mechanisms of Invadopodium Formation: The Role of the N-WASPArp2/3. Complex Pathway and Cofilin. J Cell Biol 2005; 168: 441-452. (Pubitemid 40205066)
11. Oser M, Yamaguchi H, Mader CC, Bravo-Cordero JJ, Arias M, Chen X et al. Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol 2009; 186: 571-587.
12. Patel AS, Schechter GL, Wasilenko WJ, Somers KD. Overexpression of EMS1/ cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 1998; 16: 3227-3232. (Pubitemid 28330420)
13. Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M et al. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001; 61: 6906-6911. (Pubitemid 32896517)
14. Chuma M, Sakamoto M, Yasuda J, Fujii G, Nakanishi K, Tsuchiya A et al. Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol 2004; 41: 629-636. (Pubitemid 39297799)
15. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 1995; 159: 83-96.
16. Weaver AM. Cortactin in tumor invasiveness. Cancer Lett 2008; 265: 157-166.
17. Goswami S, Philippar U, Sun D, Patsialou A, Avraham J, Wang W et al. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 2009; 26: 153-159.
18. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S et al. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 2008; 15: 813-828.
19. Gertler F, Condeelis J. Metastasis: tumor cells becoming MENAcing. Trends Cell Biol 2011; 21: 81-90.
20. Roussos ET, Wang Y, Wyckoff JB, Sellers RS, Wang W, Li J et al. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Breast Cancer Res 2010; 12: R101.
21. Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y et al. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci 2011; 124: 2120-2131.
22. Courtneidge SA, Azucena EF, Pass I, Seals DF, Tesfay L. The SRC substrate Tks5, podosomes (invadopodia), and cancer cell invasion. Cold Spring Harb Symp Quant Biol 2005; 70: 167-171. (Pubitemid 44124868)
23. Seals DF, Azucena Jr. EF, Pass I, Tesfay L, Gordon R, Woodrow M et al. The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 2005; 7: 155-165. (Pubitemid 40248341)
24. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011; 19: 372-386.
25. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM et al. The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem 2003; 278: 16844-16851. (Pubitemid 36799554)
26. Oikawa T, Itoh T, Takenawa T. Sequential signals toward podosome formation in NIH-src cells. J Cell Biol 2008; 182: 157-169. (Pubitemid 352008629)
27. Crimaldi L, Courtneidge SA, Gimona M. Tks5 recruits AFAP-110, p190RhoGAP, and cortactin for podosome formation. Exp Cell Res 2009; 315: 2581-2592.
28. Diaz B, Shani G, Pass I, Anderson D, Quintavalle M, Courtneidge SA. Tks5- dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci Signal 2009; 2: ra53.
29. Buschman MD, Bromann PA, Cejudo-Martin P, Wen F, Pass I, Courtneidge SA. The novel adaptor protein Tks4 (SH3PXD2B) is required for functional podosome formation. Mol Biol Cell 2009; 20: 1302-1311.
30. Blouw B, Seals DF, Pass I, Diaz B, Courtneidge SA. A role for the podosome/ invadopodia scaffold protein Tks5 in tumor growth in vivo. Eur J Cell Biol 2008; 87: 555-567.
31. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6: 227-239. (Pubitemid 43292566)
32. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003; 532: 91-107. (Pubitemid 37176782)
33. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000; 11: 2387-2401. (Pubitemid 30489922)
34. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446-2451. (Pubitemid 27058534)
35. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J et al. Membranetype matrix metalloproteinases1 and2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-757. (Pubitemid 28022492)
36. Fosang AJ, Last K, Fujii Y, Seiki M, Okada Y. Membrane-type1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett 1998; 430: 186-190. (Pubitemid 28337909)
37. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-624.
38. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001; 263: 209-223. (Pubitemid 32989095)
39. Toth M, Chvyrkova I, Bernardo MM, Hernandez-Barrantes S, Fridman R. Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 2003; 308: 386-395. (Pubitemid 36937191)
40. Yu X, Zech T, McDonald L, Gonzalez EG, Li A, Macpherson I et al. N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J Cell Biol 2012; 199: 527-544.
41. Steffen A, Le Dez G, Poincloux R, Recchi C, Nassoy P, Rottner K et al. MT1-MMPdependent invasion is regulated by TI-VAMP/VAMP7. Curr Biol 2008; 18: 926-931.
42. Bravo-Cordero JJ, Marrero-Diaz R, Megias D, Genis L, Garcia-Grande A, Garcia MA et al. MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J 2007; 26: 1499-1510. (Pubitemid 46480932)
43. Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009; 122: 3015-3024.
44. Nyalendo C, Beaulieu E, Sartelet H, Michaud M, Fontaine N, Gingras D et al. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 2008; 29: 1655-1664.
45. Nyalendo C, Michaud M, Beaulieu E, Roghi C, Murphy G, Gingras D et al. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem 2007; 282: 15690-15699. (Pubitemid 47093303)
46. Eisenach PA, de Sampaio PC, Murphy G, Roghi C. Membrane type1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen. J Biol Chem 2012; 287: 11533-11545.
47. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174. (Pubitemid 37328786)
48. Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 2008; 27: 3274-3281. (Pubitemid 351733384)
49. Perentes JY, Kirkpatrick ND, Nagano S, Smith EY, Shaver CM, Sgroi D et al. Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. Cancer Res 2011; 71: 4527-4538.
50. Devy L, Dransfield DT. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem Res Int 2011; 2011: 191670.
51. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27.
52. Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009; 69: 1517-1526.
53. Basu B, Correa de Sampaio P, Mohammed H, Fogarasi M, Corrie P, Watkins NA et al. Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Int J Biochem Cell Biol 2012; 44: 393-403.
54. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17: 7-30. (Pubitemid 36062504)
55. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 2008; 40: 1685-1702.
56. Moss ML, Lambert MH. Shedding of membrane proteins by ADAM family proteases. Essays Biochem 2002; 38: 141-153. (Pubitemid 36589200)
57. Albrechtsen R, Stautz D, Sanjay A, Kveiborg M, Wewer UM. Extracellular engagement of ADAM12 induces clusters of invadopodia with localized ectodomain shedding activity. Exp Cell Res 2011; 317: 195-209.
58. Diaz B, Yuen A, Iizuka S, Higashiyama S, Courtneidge SA. Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J Cell Biol 2013; 201: 279-292.
59. Handbook of proteolytic enzymes, volumes 1,2 and 3. Third edition, Anticancer Res 2013; 33: 2345.
60. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004; 279: 51323-51330. (Pubitemid 40017878)
61. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, Holck P et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 2005; 65: 4754-4761. (Pubitemid 40740812)
62. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem 2011; 286: 20758-20768.
63. Meadows SA, Edosada CY, Mayeda M, Tran T, Quan C, Raab H et al. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization. Biochemistry 2007; 46: 4598-4605. (Pubitemid 46628629)
64. O'Brien P, O'Connor BF. Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 2008; 1784: 1130-1145.
65. Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S, Chen WT. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 2006; 66: 4652-4661.
66. Mueller SC, Ghersi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem 1999; 274: 24947-24952.
67. Christiansen VJ, Jackson KW, Lee KN, McKee PA. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys 2007; 457: 177-186. (Pubitemid 46048698)
68. Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004; 36: 408-421. (Pubitemid 37542440)
69. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M et al. Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res 2006; 66: 9977-9985. (Pubitemid 44672050)
70. Santos AM, Jung J, Aziz N, Kissil JL, Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119: 3613-3625.
71. Pure E. The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets 2009; 13: 967-973.
72. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13: 1736-1741. (Pubitemid 46952939)
73. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330: 827-830.
74. Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003; 26: 44-48. (Pubitemid 36302438)
75. Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther 2007; 6: 1691-1699. (Pubitemid 351590302)
76. Eager RM, Cunningham CC, Senzer NN, Stephenson Jr. J, Anthony SP, O'Day SJ et al. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer 2009; 9: 263.
77. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 2005; 65: 11156-11163. (Pubitemid 41713387)
78. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-1962. (Pubitemid 44033319)
79. Fischer E, Chaitanya K, Wuest T, Wadle A, Scott AM, van den Broek M et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res 2012; 18: 6208-6218.
80. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358. (Pubitemid 36791891)
81. Chen WT, Chen JM, Parsons SJ, Parsons JT. Local degradation of fibronectin at sites of expression of the transforming gene product pp60src. Nature 1985; 316: 156-158. (Pubitemid 15073680)
82. Balzer EM, Whipple RA, Thompson K, Boggs AE, Slovic J, Cho EH et al. c-Src differentially regulates the functions of microtentacles and invadopodia. Oncogene 2010; 29: 6402-6408.
83. Kelley LC, Ammer AG, Hayes KE, Martin KH, Machida K, Jia L et al. Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation. J Cell Sci 2010; 123: 3923-3932.
84. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 2011; 71: 1730-1741.
85. Chan PC, Chen HC. p120RasGAP-mediated activation of c-Src is critical for oncogenic Ras to induce tumor invasion. Cancer Res 2012; 72: 2405-2415.
86. Sanchez-Bailon MP, Calcabrini A, Gomez-Dominguez D, Morte B, Martin-Forero E, Gomez-Lopez G et al. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal 2012; 24: 1276-1286.
87. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4: 470-480. (Pubitemid 38745532)
88. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6: 209-214. (Pubitemid 39222033)
89. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
90. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94: 344-351. (Pubitemid 34081362)
91. Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, O'Malley BW et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci USA 2009; 106: 151-156.
92. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006; 168: 962-972. (Pubitemid 43327748)
93. Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2010; 16: 566-578.
94. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res Treat 2012; 132: 391-409.
95. Naing A, Cohen R, Dy GK, Hong DS, Dyster L, Hangauer DG et al. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs 2013; 31: 967-973.
96. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 2008; 27: 4385-4391.
97. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006; 66: 5648-5655. (Pubitemid 43927117)
98. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, Pendergast AM. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 13: 2400-2411. (Pubitemid 29453611)
99. Smith-Pearson PS, Greuber EK, Yogalingam G, Pendergast AM. Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem 2010; 285: 40201-40211.
100. Gil-Henn H, Patsialou A, Wang Y, Warren MS, Condeelis JS, Koleske AJ. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene 2013; 32: 2622-2630.
101. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007; 67: 1580-1588. (Pubitemid 46383382)
102. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16: 3526-3532.
103. Mueller SC, Chen WT. Cellular invasion into matrix beads: localization of beta1 integrins and fibronectin to the invadopodia. J Cell Sci 1991; 99(Pt 2): 213-225. (Pubitemid 21925010)
104. Destaing O, Planus E, Bouvard D, Oddou C, Badowski C, Bossy V et al. beta1A integrin is a master regulator of invadosome organization and function. Mol Biol Cell 2010; 21: 4108-4119.
105. Branch KM, Hoshino D, Weaver AM. Adhesion rings surround invadopodia and promote maturation. Biol Open 2012; 1: 711-722.
106. Beaty BT, Sharma VP, Bravo-Cordero JJ, Simpson MA, Eddy RJ, Koleske AJ et al. beta1 integrin regulates Arg to promote invadopodial maturation and matrix degradation. Mol Biol Cell 2013; 24: 1661-1675.
107. Nakahara H, Nomizu M, Akiyama SK, Yamada Y, Yeh Y, Chen WT. A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. J Biol Chem 1996; 271: 27221-27224. (Pubitemid 26367269)
108. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
109. Huck L, Pontier SM, Zuo DM, Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010; 107: 15559-15564.
110. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
111. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939. (Pubitemid 38798858)
112. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-736.
113. Zavadil J, Bottinger EP. TGF-b and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
114. Pignatelli J, Tumbarello DA, Schmidt RP, Turner CE. Hic-5 promotes invadopodia formation and invasion during TGF-beta-induced epithelial- mesenchymal transition. J Cell Biol 2012; 197: 421-437.
115. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
116. Parekh A, Weaver AM. Regulation of cancer invasiveness by the physical extracellular matrix environment. Cell Adh Migr 2009; 3: 288-292.
117. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54. (Pubitemid 36068681)
118. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005; 8: 241-254. (Pubitemid 41317594)
119. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
120. Alexander NR, Branch KM, Parekh A, Clark ES, Iwueke IC, Guelcher SA et al. Extracellular matrix rigidity promotes invadopodia activity. Curr Biol 2008; 18: 1295-1299.
121. Parekh A, Ruppender NS, Branch KM, Sewell-Loftin MK, Lin J, Boyer PD et al. Sensing and modulation of invadopodia across a wide range of rigidities. Biophys J 2011; 100: 573-582.
122. Yamaguchi H. Pathological roles of invadopodia in cancer invasion and metastasis. Eur J Cell Biol 2012; 91: 902-907.
123. Gligorijevic B, Wyckoff J, Yamaguchi H, Wang Y, Roussos ET, Condeelis J. N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J Cell Sci 2012; 125: 724-734.
124. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol 2005; 17: 559-564. (Pubitemid 41267171)
125. Ito S, Nakanishi H, Ikehara Y, Kato T, Kasai Y, Ito K et al. Real-time observation of micrometastasis formation in the living mouse liver using a green fluorescent protein gene-tagged rat tongue carcinoma cell line. Int J Cancer 2001; 93: 212-217. (Pubitemid 32574277)
126. Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S et al. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010; 123: 2332-2341.
127. Steeg PS. Perspective: the right trials. Nature 2012; 485: S58-S59.